
Dallas-based startup works on new lung disease drugs. Now, the company received a $80M funding round. The round was led by (also Dallas-based) single family office .Funding for an innovative biotech startup from DallasReCode Therapeutics was founded by Daniel Siegwart and Philip Thomas, who met at University of Texas Southwestern Medical Center. The company works on diverse drugs for “r primary ciliary dyskinesia (PCD) and nonsense mutations in cystic fibrosis (CF)”. ReCode’s drugs are based on its “proprietary non-viral lipid nanoparticle platform”. The Texas startup wants to file a investigational drug application with the FDA by 2021.Blanton Single Family Office from Dallas as lead investorNow, ReCode Therapeutics received an $80M Series A funding round for its further development. The round was led by Cold Ventures and healthcare investment firm OrbiMed Advisors. Another participating investor was Hunt Technology Ventures from Dallas. Also part of the funding round: a merger with Menlo Park startup TranscriptTX, whose CEO David Lockhart will run the combined company in the future. Lead investor Colt Ventures is the single family office of Darren Blanton. Colt Ventures invests in public company (like Intrexon or Rocket Pharma) as well as private biotech firms.Picture source: via UnsplashSource: Relevant family office articlesRelevant family office lists €149,99 including VAT Rated 4.00 out of 5 €399,99 including VAT Rated 5.00 out of 5 €799,99 including VAT Rated 4.67 out of 5 €499,99 including VAT
User Comments1. L.
Young: Comment sample 1...2. Layla
Baker: Comment sample 2...3. Chloe H.: Comment sample 3...4. J.
Walker: Comment sample 4...5. Lily N.: Comment sample 5...Editor's NoteThis article was refined for clarity, structure, and user experience.

(Editors: admin)
Disclaimer & Copyright Notice:
This article is edited and compiled by the editorial team at WealthShield Asia based on publicly available information. It is intended for informational purposes only and does not constitute legal, financial, or investment advice.
We respect intellectual property rights. If you believe that any part of this article infringes upon your copyright or other legal rights, please contact us at
admin@wealthshield.asia. We will promptly review and remove the content if necessary.
All rights reserved. Unauthorized reproduction or redistribution is prohibited.